Skip to main content
SpringerLink
Log in

A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy

  • Original Article
  • Published:
Lasers in Medical Science Aims and scope Submit manuscript

Abstract

To compare the efficacy of 50% threshold power with 25% threshold power of 577-nm subthreshold micropulse laser (SMPL) for acute central serous chorioretinopathy (CSC). Prospective, interventional, non-randomized, comparative case series. A total of 54 patients (54 eyes) with acute CSC were enrolled. Twenty-four eyes received 25% threshold power and 30 eyes received 50% threshold power of 577-nm SMPL. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and complete absorption of subretinal fluid (SRF) were evaluated at 1 month and 3 months. The complete absorption rate of SRF in the 50% power group was significantly greater than that in the 25% power group at 1 month (70.0% vs 25.0%, p < 0.001) and at 3 months (83.3% vs 54.2%, p < 0.001). Mean BCVA improved from 0.34 ± 0.20 LogMAR to 0.02 ± 0.13 LogMAR in the 50% power group and from 0.27 ± 0.15 LogMAR to 0.14 ± 0.21 LogMAR in the 25% power group with a significant difference between the two groups after 3 months (p = 0.027). In the 50% power group, the CMT decreased from 491.6 ± 154.8 μm at baseline to 231.3 ± 92.3 μm at 1 month and 228.2 ± 88.1 μm at 3 months, and in the 25% power group, the CMT decreased from 444.9 ± 164.1 to 306.8 ± 102.6 μm at 1 month and 254.5 ± 101.7 μm at 3 months. There was statistical difference of CMT at 1 month (p = 0.009) but no significant difference at 3 months between the two groups (p = 0.232). SMPL with 50% threshold power may be more effective than 25% threshold power for acute CSC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. An SH, Kwon YH (2016) Effect of a topical nonsteroidal anti-inflammatory agent (0.1% pranoprofen) on acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254(8):1489–1496. https://doi.org/10.1007/s00417-015-3215-8

    Article  CAS  PubMed  Google Scholar 

  2. Wong KH, Lau KP, Chhablani J, Tao Y, Li Q, Wong IY (2016) Central serous chorioretinopathy: what we have learnt so far. Acta Ophthalmol 94(4):321–325. https://doi.org/10.1111/aos.12779

    Article  PubMed  Google Scholar 

  3. Yannuzzi LA (1987) Type-A behavior and central serous chorioretinopathy. Retina 7(2):111–131

    Article  CAS  PubMed  Google Scholar 

  4. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118. https://doi.org/10.1016/j.preteyeres.2015.05.003

    Article  CAS  PubMed  Google Scholar 

  5. Iacono P, Battaglia Parodi M, Falcomata B, Bandello F (2015) Central serous chorioretinopathy treatments: a mini review. Ophthalmic Res 55(2):76–83. https://doi.org/10.1159/000441502

    Article  CAS  PubMed  Google Scholar 

  6. Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE (2002) Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22(1):19–24

    Article  PubMed  Google Scholar 

  7. Fok AC, Chan PP, Lam DS, Lai TY (2011) Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res 46(3):160–163. https://doi.org/10.1159/000324599

    Article  PubMed  Google Scholar 

  8. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 115(1):169–173. https://doi.org/10.1016/j.ophtha.2007.02.032

    Article  PubMed  Google Scholar 

  9. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115(10):1756–1765. https://doi.org/10.1016/j.ophtha.2008.04.014

    Article  PubMed  Google Scholar 

  10. Khosla PK, Rana SS, Tewari HK, Azad RU, Talwar D (1997) Evaluation of visual function following argon laser photocoagulation in central serous retinopathy. Ophthalmic Surg Lasers 28(8):693–697

    CAS  PubMed  Google Scholar 

  11. Zhao MW, Zhou P, Xiao HX, Lv YS, Li CA, Liu GD, Li XX (2009) Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina 29(8):1155–1161. https://doi.org/10.1097/IAE.0b013e3181a6c028

    Article  PubMed  Google Scholar 

  12. Schatz H, Yannuzzi LA, Gitter KA (2012) Subretinal neovascularization following argon laser photocoagulation treatment for central serous chorioretinopathy: complication or misdiagnosis? 1975. Retina 32(Suppl 1):OP893–OP906

    Article  PubMed  Google Scholar 

  13. Koytak A, Erol K, Coskun E, Asik N, Ozturk H, Ozerturk Y (2010) Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 30(10):1698–1703. https://doi.org/10.1097/IAE.0b013e3181da4354

    Article  PubMed  Google Scholar 

  14. Kim SW, Oh J, Oh IK, Huh K (2009) Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 40(3):300–303

    Article  CAS  PubMed  Google Scholar 

  15. Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G (2010) Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol 55(6):516–530. https://doi.org/10.1016/j.survophthal.2010.02.005

    Article  PubMed  Google Scholar 

  16. Kwon YH, Lee DK, Kwon OW (2014) The short-term efficacy of subthreshold micropulse yellow (577-nm) laser photocoagulation for diabetic macular edema. Korean J Ophthalmol 28(5):379–385. https://doi.org/10.3341/kjo.2014.28.5.379

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ohkoshi K, Yamaguchi T (2010) Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol 149(1):133–139. https://doi.org/10.1016/j.ajo.2009.08.010

    Article  PubMed  Google Scholar 

  18. Yadav NK, Jayadev C, Rajendran A, Nagpal M (2014) Recent developments in retinal lasers and delivery systems. Indian J Ophthalmol 62(1):50–54. https://doi.org/10.4103/0301-4738.126179

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dabir S, Shetty B, Shetty R, Medscape (2015) Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye (Lond) 29(2):258–264; quiz 265. https://doi.org/10.1038/eye.2014.315

    Article  CAS  Google Scholar 

  20. Scholz P, Altay L, Fauser S (2016) Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond). https://doi.org/10.1038/eye.2016.142

  21. Kim JY, Park HS, Kim SY (2015) Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 253(12):2129–2135. https://doi.org/10.1007/s00417-015-2965-7

    Article  PubMed  Google Scholar 

  22. Roisman L, Magalhaes FP, Lavinsky D, Moraes N, Hirai FE, Cardillo JA, Farah ME (2013) Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina 44(5):465–470. https://doi.org/10.3928/23258160-20130909-08

    Article  PubMed  Google Scholar 

  23. Sun X, Shuai Y, Fang W, Li J, Ge W, Yuan S, Liu Q (2017) Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-311096

  24. Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D (2014) Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 34(1):87–97. https://doi.org/10.1097/IAE.0b013e3182993edc

    Article  PubMed  Google Scholar 

  25. Lavinsky D, Palanker D (2015) Nondamaging photothermal therapy for the retina: initial clinical experience with chronic central serous retinopathy. Retina 35(2):213–222. https://doi.org/10.1097/IAE.0000000000000340

    Article  CAS  PubMed  Google Scholar 

  26. Maruko I, Koizumi H, Hasegawa T, Arakawa H, Iida T (2017) Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy. PLoS One 12(8):e0184112. https://doi.org/10.1371/journal.pone.0184112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank all staff involved in the care of patient presented in this study.

Financial support

Supported by National Natural Science Foundation of China (81670866).

Author information

Authors and Affiliations

  1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou City, China

    Lijun Zhou, Kunbei Lai, Chuangxin Huang, Fabao Xu, Yajun Gong, Tao Li, Lin Lu & Chenjin Jin

  2. Optegra Eye Hospital, London, UK

    Victor Chong

  3. The First People’s Hospital of Kashgar, Kashgar, Xinjiang Autonomous Region, China

    Maimaitiaili Youlidaxi

Authors
  1. Lijun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kunbei Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chuangxin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fabao Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yajun Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maimaitiaili Youlidaxi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lin Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chenjin Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chenjin Jin.

Ethics declarations

Conflict of interest

All authors have no financial or other conflicts of interest concerning this study. VC is a consultant of Quantel Medical and an employee of Boehringer Ingelheim.

Informed consent

Written informed consents were obtained from the patients before treatment.

Ethical approval

This study was approved by the Ethics Committee of Zhongshan Ophthalmic Center of Sun Yat-Sen University and was conducted in adherence with the tenets of the Declaration of Helsinki.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, L., Chong, V., Lai, K. et al. A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy. Lasers Med Sci 34, 1345–1351 (2019). https://doi.org/10.1007/s10103-019-02721-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10103-019-02721-8

Keywords

Search

Navigation